Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report) was up 15.3% during trading on Monday . The company traded as high as $4.15 and last traded at $4.15. Approximately 100 shares changed hands during trading, a decline of 89% from the average daily volume of 900 shares. The stock had previously closed at $3.60.
Molecular Partners Price Performance
The business’s 50-day simple moving average is $3.57 and its two-hundred day simple moving average is $3.92.
About Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Featured Articles
- Five stocks we like better than Molecular Partners
- The Most Important Warren Buffett Stock for Investors: His Own
- What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health
- EV Stocks and How to Profit from Them
- 3 Stocks Most Likely to Split in 2026
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- ChargePoint’s Comeback Story: Why This EV Stock Is Charging Up Again
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
